Companies/US/SPRO

SPERO THERAPEUTICS, INC.

Income flow

Annual
SPRO 10-K Income StatementPeriod 2025-12-31Source 10-K
Collaboration Revenue Related Party$8MCollaboration Revenue$2MGrant$1MGrant Revenue$1MSPRTwo Zero Six$16,985Revenue$13M+3293% Y/YNet profit$9M+113% Y/YTax$261,000

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2025-12-31 · 10-K · USD
By activity
By activity$74M
  • Collaboration Revenue Related Party$47M63.5%
  • Collaboration Revenue$13M17.0%
  • Grant$7M9.7%
  • Grant Revenue$7M9.7%
  • SPRTwo Zero Six$100,0000.1%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).0.00%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).0PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.0.0%Shares outTotal shares currently outstanding (issued and not retired).58.2MFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).47.1M

Valuation

Trailing PE 15.5 (2025-12-31)PE trend

Fiscal PE1

PeriodEPSClosePE
2025-12-310.152.3315.5

PE = stored close ÷ as-filed diluted EPS (annual 10-K / 20-F). Not a vendor PE series.